Researchers Find Effective Biomarker for Predicting Severity of Myositis-Associated Interstitial Lung Disease

A team of researchers recently evaluated a new biomarker in interstitial lung disease to see whether or not it could predict disease severity and ultimately mortality. The Biomarker Surfactant protein…

Continue Reading Researchers Find Effective Biomarker for Predicting Severity of Myositis-Associated Interstitial Lung Disease
First Ever Test Which can Predict Progression in Idiopathic Pulmonary Fibrosis is Making Progress
source: pixabay.com

First Ever Test Which can Predict Progression in Idiopathic Pulmonary Fibrosis is Making Progress

Idiopathic Pulmonary Fibrosis Progression Veracyte has just signed a deal with Yale University which will help them develop the very first test which can predict disease progression for idiopathic pulmonary…

Continue Reading First Ever Test Which can Predict Progression in Idiopathic Pulmonary Fibrosis is Making Progress
New Genetic Test Can Predict Disease Progression of Idiopathic Pulmonary Fibrosis
Source: Pixabay

New Genetic Test Can Predict Disease Progression of Idiopathic Pulmonary Fibrosis

Predicting the disease progression of idiopathic pulmonary fibrosis (IPF) is extremely important, as this condition progresses differently depending on the affected individual. Knowing if one has a poor outcome while…

Continue Reading New Genetic Test Can Predict Disease Progression of Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis Exacerbated by Bacterial Protein Fragment, Study Finds
kalhh / Pixabay

Idiopathic Pulmonary Fibrosis Exacerbated by Bacterial Protein Fragment, Study Finds

  As stated in a press release from the University of Illinois at Urbana-Champaign, researchers have discovered a bacterial protein fragment that is destructive to lung tissue. This can rapidly…

Continue Reading Idiopathic Pulmonary Fibrosis Exacerbated by Bacterial Protein Fragment, Study Finds
Telehealth Increases Convenience For Caregivers and Transplant Recipients
source: pixabay.com

Telehealth Increases Convenience For Caregivers and Transplant Recipients

According to a story from mHealth Intelligence, the University of Alabama has found success with using telehealth to check in with kidney disease patients that are on dialysis. Now, it…

Continue Reading Telehealth Increases Convenience For Caregivers and Transplant Recipients
A Recent Study from Yale Tracks the Progression of Scarring in Idiopathic Pulmonary Fibrosis
source: pixabay.com

A Recent Study from Yale Tracks the Progression of Scarring in Idiopathic Pulmonary Fibrosis

According to a story from EurekAlert!, a collaborative study headed by researchers from Yale University has furthered the understanding of the mechanisms and progression of fibrosis (scarring) in patients with…

Continue Reading A Recent Study from Yale Tracks the Progression of Scarring in Idiopathic Pulmonary Fibrosis
Progressive Fibrosing Interstitial Lung Disease Drug Candidate Ofev Granted Breakthrough Therapy Status
source: pixabay.com

Progressive Fibrosing Interstitial Lung Disease Drug Candidate Ofev Granted Breakthrough Therapy Status

According to a publication from Scleroderma News, the American Food and Drug Administration (FDA) recently granted Breakthrough Therapy status to Ofev (generic name nintedanib), as a treatment for progressive fibrosing…

Continue Reading Progressive Fibrosing Interstitial Lung Disease Drug Candidate Ofev Granted Breakthrough Therapy Status
A Potential Treatment for Idiopathic Pulmonary Fibrosis Earns Orphan Drug Designation
Pexels / Pixabay

A Potential Treatment for Idiopathic Pulmonary Fibrosis Earns Orphan Drug Designation

According to a story from Financial Buzz, the biotherapeutics company Bellerophon Therapeutics Inc. has recently announced that it has earned Orphan Drug designation from the US Food and Drug Administration…

Continue Reading A Potential Treatment for Idiopathic Pulmonary Fibrosis Earns Orphan Drug Designation
Making History: First Drug Approved for Scleroderma-Associated Interstitial Lung Disease
TeroVesalainen / Pixabay

Making History: First Drug Approved for Scleroderma-Associated Interstitial Lung Disease

According to a story from finanzen.at, the drug nintedanib (marketed as Ofev) has officially been approved by the US Food and Drug Administration (FDA) as a treatment for interstitial lung…

Continue Reading Making History: First Drug Approved for Scleroderma-Associated Interstitial Lung Disease
This Idiopathic Pulmonary Fibrosis Clinic is Improving Patient Quality of Life
truthseeker08 / Pixabay

This Idiopathic Pulmonary Fibrosis Clinic is Improving Patient Quality of Life

According to a story from Medical Xpress, the Alberta Health Services' Kaye Edmonton Interstitial Lung Disease Clinic is taking a more patient-centered approach to palliative care for patients with idiopathic…

Continue Reading This Idiopathic Pulmonary Fibrosis Clinic is Improving Patient Quality of Life
Phase 2a Trial of Experimental Pulmonary Arterial Hypertension Drug Begins
source: pixabay.com

Phase 2a Trial of Experimental Pulmonary Arterial Hypertension Drug Begins

According to a story from BioSpace, the biopharmaceutical company Altavant Sciences has recently announced that the first patient has been dosed in a phase 2a proof of concept trial. This…

Continue Reading Phase 2a Trial of Experimental Pulmonary Arterial Hypertension Drug Begins

FDA Advisory Committee Recommends Approval of Drug to Treat Interstitial Lung Disease Caused by Systemic Sclerosis

According to a story from Healio, the US Food and Drug Administration's (FDA) Arthritis Advisory Committee recently voted 10-7 in favor of recommending the drug nintedanib as a treatment for…

Continue Reading FDA Advisory Committee Recommends Approval of Drug to Treat Interstitial Lung Disease Caused by Systemic Sclerosis
First Patient Dosed in Phase 3 Study of Experimental Idiopathic Pulmonary Fibrosis Drug
source: pixabay.com

First Patient Dosed in Phase 3 Study of Experimental Idiopathic Pulmonary Fibrosis Drug

According to a press release from the San Francisco-based FibroGen, Inc., the first patient has been dosed in the Company's phase 3 clinical study of the experimental drug pamrevlumab for…

Continue Reading First Patient Dosed in Phase 3 Study of Experimental Idiopathic Pulmonary Fibrosis Drug

FDA Clears Phase 2 Trial for Possible Idiopathic Pulmonary Fibrosis Drug

According to a story from BioPortfolio, the biopharmaceutical company Genkyotex has recently announced that the US Food and Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application.…

Continue Reading FDA Clears Phase 2 Trial for Possible Idiopathic Pulmonary Fibrosis Drug
80 Year Old With Pulmonary Fibrosis Proves Some Seniors are Transplant-Viable
Source: Pixabay

80 Year Old With Pulmonary Fibrosis Proves Some Seniors are Transplant-Viable

According to a publication from the Oklahoma Nursing Times, Kenneth Wyatt celebrated his 80th birthday this past June 4th. The happy occasion also marked almost five months exactly since Wyatt…

Continue Reading 80 Year Old With Pulmonary Fibrosis Proves Some Seniors are Transplant-Viable
Late Stage Idiopathic Pulmonary Fibrosis Trial Faces Recruitment Woes
mcmurryjulie / Pixabay

Late Stage Idiopathic Pulmonary Fibrosis Trial Faces Recruitment Woes

According to a story from Pharmaceutical Technology, the drug developer FibroGen's phase 3 clinical trial testing pamrevlumab as a treatment for idiopathic pulmonary fibrosis could be in trouble. While the…

Continue Reading Late Stage Idiopathic Pulmonary Fibrosis Trial Faces Recruitment Woes

Presentations at the ATS Conference Demonstrate the Value of the Pulmonary Fibrosis Foundation’s Patient Registry

At the 2019 American Thoracic Society Conference this year multiple presentations demonstrated the importance of the Pulmonary Fibrosis Foundation's Patient Registry. About the Registry This registry was created by the Pulmonary…

Continue Reading Presentations at the ATS Conference Demonstrate the Value of the Pulmonary Fibrosis Foundation’s Patient Registry
Development Progresses on a Possible Therapy for Idiopathic Pulmonary Fibrosis
source: pixabay.com

Development Progresses on a Possible Therapy for Idiopathic Pulmonary Fibrosis

According to a story from Market Screener, the drug developer Reviva Pharmaceuticals, Inc. recently announced that it has completed a recent meeting with officials from the US Food and Drug…

Continue Reading Development Progresses on a Possible Therapy for Idiopathic Pulmonary Fibrosis

Patient Registry Reveals Critical Information About Idiopathic Pulmonary Fibrosis

According to a story from blogs.biomedcentral.com, the findings from the IPF-PRO Registry, which is a US-based registry for idiopathic pulmonary fibrosis patients, were recently published. Patient registries are a critical…

Continue Reading Patient Registry Reveals Critical Information About Idiopathic Pulmonary Fibrosis

Mouse Model Continues to Show Efficacy of GKT831 for Treating Cholestatic Fibrosis in Primary Biliary Cholangitis

Preclinical data supporting the efficacy of GKT831 as a potential therapy for cholestatic fibrosis has just been published in the Journal of Hepatology. GKT831 GKT831 is both a NOX1 enzyme and…

Continue Reading Mouse Model Continues to Show Efficacy of GKT831 for Treating Cholestatic Fibrosis in Primary Biliary Cholangitis
Drug Displays Potential in Treating Lung Symptoms of Systemic Sclerosis
Myriams-Fotos / Pixabay

Drug Displays Potential in Treating Lung Symptoms of Systemic Sclerosis

According to a story from Boehringer Ingelheim Pharmaceuticals, Inc., the company has recently announced positive results from a phase 3 clinical trial testing the company's drug nintedanib (marketed as Ofev)…

Continue Reading Drug Displays Potential in Treating Lung Symptoms of Systemic Sclerosis
Close Menu